IMR Press / FBE / Volume 6 / Issue 2 / DOI: 10.2741/709

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
Pharmacoresistant epilepsy and nanotechnology
Show Less
1 Department of Pharmacobiology, Center of Research and Advanced Studies, Mexico
2 Polymer, Biopolymer Research Group, Center of Research and Advanced Studies, Mexico
3 Unit for Medical Research in Neurological Diseases, National Medical Center, Mexico
4 Institute of Engineer and Technology, Autonomus University of Juarez City, Mexico
5 Institute of Cellular Biology and Neuroscience Prof, E, De Robertis, School of Medicine, UBA, Argentina

*Author to whom correspondence should be addressed.

Academic Editor: Antoni Camins

Front. Biosci. (Elite Ed) 2014, 6(2), 329–340; https://doi.org/10.2741/709
Published: 1 June 2014
(This article belongs to the Special Issue Current advances in epilepsy and neurodegeneration)
Abstract

Epilepsy is one of the most common chronic neurological disorders. Furthermore, it is associated to diminished health-related quality of life and is thus considered a major public health problem. In spite of the large number of available and ongoing development of several new antiepileptic drugs (AEDs), a high percentage of patients with epilepsy (35-40%) are resistant to pharmacotherapy. A hypothesis to explain pharmacoresistance in epilepsy suggests that overexpression of multidrug resistance proteins, such as P-glycoprotein, on the endothelium of the blood brain barrier represents a challenge for effective AED delivery and concentration levels in the brain. Proven therapeutic strategies to control pharmacoresistant epilepsy include epilepsy surgery and neuromodulation. Unfortunately, not all patients are candidates for these therapies. Nanotechnology represents an attractive strategy to overcome the limited brain access of AEDs in patients with pharmacoresistant epilepsy. This manuscript presents a review of evidences supporting this idea.

Keywords
Epilepsy
Pharmacoresistance
Drug nanocarriers
Nanoparticles
Drug transporters
Review
Share
Back to top